Literature DB >> 29178588

Early barriers to neonatal porcine islet engraftment in a dual transplant model.

K P Samy1, R P Davis1, Q Gao1, B M Martin2, M Song1, J Cano2, A B Farris3, A McDonald1, E K Gall1, C R Dove4, F V Leopardi1, T How1, K D Williams1, G R Devi1, B H Collins1, A D Kirk1,2.   

Abstract

Porcine islet xenografts have the potential to provide an inexhaustible source of islets for β cell replacement. Proof-of-concept has been established in nonhuman primates. However, significant barriers to xenoislet transplantation remain, including the poorly understood instant blood-mediated inflammatory reaction and a thorough understanding of early xeno-specific immune responses. A paucity of data exist comparing xeno-specific immune responses with alloislet (AI) responses in primates. We recently developed a dual islet transplant model, which enables direct histologic comparison of early engraftment immunobiology. In this study, we investigate early immune responses to neonatal porcine islet (NPI) xenografts compared with rhesus islet allografts at 1 hour, 24 hours, and 7 days. Within the first 24 hours after intraportal infusion, we identified greater apoptosis (caspase 3 activity and TUNEL [terminal deoxynucleotidyl transferase dUTP nick end labeling])-positive cells) of NPIs compared with AIs. Macrophage infiltration was significantly greater at 24 hours compared with 1 hour in both NPI (wild-type) and AIs. At 7 days, IgM and macrophages were highly specific for NPIs (α1,3-galactosyltransferase knockout) compared with AIs. These findings demonstrate an augmented macrophage and antibody response toward xenografts compared with allografts. These data may inform future immune or genetic manipulations required to improve xenoislet engraftment.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  alloantigen; basic (laboratory) research/science; islet transplantation; rejection: antibody-mediated (ABMR); translational research/science; xenoantigen; xenotransplantation

Mesh:

Year:  2017        PMID: 29178588      PMCID: PMC5878697          DOI: 10.1111/ajt.14601

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  55 in total

1.  Early islet damage after direct exposure of pig islets to blood: has humoral immunity been underestimated?

Authors:  Dirk J van der Windt; Marco Marigliano; Jing He; Tatyana V Votyakova; Gabriel J Echeverri; Burcin Ekser; David Ayares; Fadi G Lakkis; David K C Cooper; Massimo Trucco; Rita Bottino
Journal:  Cell Transplant       Date:  2012-07-05       Impact factor: 4.064

2.  Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States.

Authors:  D C Brennan; H A Kopetskie; P H Sayre; R Alejandro; E Cagliero; A M J Shapiro; J S Goldstein; M R DesMarais; S Booher; P J Bianchine
Journal:  Am J Transplant       Date:  2015-10-03       Impact factor: 8.086

3.  Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes.

Authors:  Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector
Journal:  Xenotransplantation       Date:  2015-03-01       Impact factor: 3.907

4.  Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function.

Authors:  P Thompson; I R Badell; M Lowe; J Cano; M Song; F Leopardi; J Avila; R Ruhil; E Strobert; G Korbutt; G Rayat; R Rajotte; N Iwakoshi; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2011-08-29       Impact factor: 8.086

5.  Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival.

Authors:  P Thompson; I R Badell; M Lowe; A Turner; J Cano; J Avila; A Azimzadeh; X Cheng; R N Pierson; B Johnson; J Robertson; M Song; F Leopardi; E Strobert; G Korbutt; G Rayat; R Rajotte; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2012-03-28       Impact factor: 8.086

6.  Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis.

Authors:  Christoph Schwarz; Sophie Mayerhoffer; Gabriela A Berlakovich; Rudolf Steininger; Thomas Soliman; Bruno Watschinger; Georg A Böhmig; Farsad Eskandary; Franz König; Ferdinand Mühlbacher; Thomas Wekerle
Journal:  Transpl Int       Date:  2015-03-06       Impact factor: 3.782

7.  The importance of tissue factor expression by porcine NICC in triggering IBMIR in the xenograft setting.

Authors:  Ming Ji; Shounan Yi; Helena Smith-Hurst; Peta Phillips; Jingjing Wu; Wayne Hawthorne; Philip O'Connell
Journal:  Transplantation       Date:  2011-04-27       Impact factor: 4.939

8.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

9.  The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-- executive summary.

Authors:  Bernhard J Hering; David K C Cooper; Emanuele Cozzi; Henk-Jan Schuurman; Gregory S Korbutt; Joachim Denner; Philip J O'Connell; Harold Y Vanderpool; Richard N Pierson
Journal:  Xenotransplantation       Date:  2009 Jul-Aug       Impact factor: 3.907

10.  Production of multiple transgenic Yucatan miniature pigs expressing human complement regulatory factors, human CD55, CD59, and H-transferase genes.

Authors:  Young-Hee Jeong; Chi-Hun Park; Gun-Hyuk Jang; Yeun-Ik Jeong; In-Sung Hwang; Yeon-Woo Jeong; Yu-Kyung Kim; Taeyoung Shin; Nam-Hyung Kim; Sang-Hwan Hyun; Eui-Bae Jeung; Woo-Suk Hwang
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more
  8 in total

1.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

2.  The role of human CD46 in early xenoislet engraftment in a dual transplant model.

Authors:  Kannan P Samy; Qimeng Gao; Robert Patrick Davis; Mingqing Song; Zachary W Fitch; Michael S Mulvihill; Andrea L MacDonald; Frank V Leopardi; Tam How; Kyha D Williams; Gayathri R Devi; Bradley H Collins; Xunrong Luo; Allan D Kirk
Journal:  Xenotransplantation       Date:  2019-06-20       Impact factor: 3.907

Review 3.  Macrophages in xenotransplantation.

Authors:  Jae Young Kim
Journal:  Korean J Transplant       Date:  2019-12-31

Review 4.  Will Genetic Engineering Carry Xenotransplantation of Pig Islets to the Clinic?

Authors:  Elisabeth Kemter; Joachim Denner; Eckhard Wolf
Journal:  Curr Diab Rep       Date:  2018-09-18       Impact factor: 4.810

Review 5.  Current Topics of Relevance to the Xenotransplantation of Free Pig Islets.

Authors:  Lisha Mou; Guanghan Shi; David K C Cooper; Ying Lu; Jiao Chen; Shufang Zhu; Jing Deng; Yuanyuan Huang; Yong Ni; Yongqiang Zhan; Zhiming Cai; Zuhui Pu
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

Review 6.  Cellular Immune Responses in Islet Xenograft Rejection.

Authors:  Min Hu; Wayne J Hawthorne; Shounan Yi; Philip J O'Connell
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

7.  Coagulation, inflammation, and CD46 transgene expression in neonatal porcine islet xenotransplantation.

Authors:  Mingqing Song; Zachary W Fitch; Kannan P Samy; Benjamin M Martin; Qimeng Gao; Robert Patrick Davis; Francis V Leopardi; Niki Huffman; Robin Schmitz; Gayathri R Devi; Bradley H Collins; Allan D Kirk
Journal:  Xenotransplantation       Date:  2021-02-22       Impact factor: 3.907

Review 8.  Therapeutic Strategies for Modulating the Extracellular Matrix to Improve Pancreatic Islet Function and Survival After Transplantation.

Authors:  Alexandra M Smink; Paul de Vos
Journal:  Curr Diab Rep       Date:  2018-05-19       Impact factor: 4.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.